Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 3:55 PM
Ignite Modification Date:
2025-12-25 @ 1:59 PM
NCT ID:
NCT05184192
Group ID:
EG000
Title:
Gabapentin
Description:
This arm will be given the active treatment, oral Letco (gabapentin) gelatin capsules of 300mg each.
Up to the first four weeks will be a titration period (week 1 300mg TID, week 2 600mg TID, week 3 900mg TID, week 4 1,200mg TID) as tolerated. If intolerable adverse reactions occur, the dosage will be decreased to prior tolerable dose (e.g., if 900mg TID is intolerable, dose will be decreased to 600mg TID).
The following eight weeks will be fixed dose, the highest tolerable dose from the titration period.
Up to two weeks will be a taper down tailored to the maximum dose the participant reached during the titration and fixed periods.
A maximum 14 weeks will mark the end of active treatment. Follow-up assessments will be conducted 4 weeks after completion of the taper-down period.
Gabapentin gelatin capsules 300mg: Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
18
Other Number Affected:
10
Other Number At Risk:
18
Study:
NCT05184192
Results Section:
NCT05184192
Adverse Events Module:
NCT05184192